ArticleIJID regions2026
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The emergence of carbapenem-resistant Methods: A total of 80 wound swabs were collected, and CRPA were isolated on selective plates. Antibiograms by disc diffusion and short-read whole-genome sequencing were performed on all CRPA. Resistance genes were looked for using the Center for Genomic Epidemiology (CGE) tools and phylogenetic analysis were carried out using core genome multilocus sequence typing (ST) and single-nucleotide polymorphism-based methodologies. Results: Over the 80 samples, 13 CRPA (16.3%) were identified, which were also mostly resistant to amikacin, ceftazidime, cefepime, and aztreonam. Colistin was the only antibiotic for which all isolates remained susceptible. Two (2.5%) isolates carried an acquired carbapenemase gene ( Conclusions: This study adds important knowledge on the CRPA clones and carbapenem-resistance mechanisms circulating in Iraq and offers baseline data to be compared with further surveillance studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.